Yusuke Watanabe1, Tomohiko Shinkawa2, Sho Endo2, Yuji Abe2, Kazuyoshi Nishihara2, Toru Nakano2. 1. Department of Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, 802-0077, Japan. wyuusuke@surg1.med.kyushu-u.ac.jp. 2. Department of Surgery, Kitakyushu Municipal Medical Center, 2-1-1 Bashaku, Kokurakita-ku, Kitakyushu, 802-0077, Japan.
Abstract
BACKGROUND: The benefit of pancreatectomy for elderly patients with pancreatic ductal adenocarcinoma (PDAC) remains controversial. Moreover, adjuvant chemotherapy (AC) for elderly patients has not been fully evaluated. We investigated the long-term outcomes after pancreatectomy for PDAC in elderly patients with special reference to AC. METHODS: The medical records of 123 patients who underwent pancreatectomy for PDAC from 2007 to 2016 were retrospectively reviewed. The patients were divided into two groups: young (<75 years) and elderly patients (≥75 years). RESULTS: The study population comprised 91 young and 32 elderly patients. The postoperative clinical courses were not different between the two groups. AC was more frequently administered to young (85%) than elderly patients (66%; P = 0.04). The weekly dose of tegafur/gimeracil/oteracil potassium (S1) for AC was significantly lower in elderly (median 423 mg/m2) than young patients (median 491 mg/m2; P = 0.02). The prevalence of adverse events and the completion rate of AC were not significantly different between the two groups. There were no significant differences in recurrence-free survival (P = 0.73) or overall survival (P = 0.68) between the two groups in univariate analysis. Receipt of AC was not a significant independent factor for survival, and completion of planned AC was a significant independent factor for recurrence-free survival and overall survival in multivariate analysis. CONCLUSIONS: The benefit of pancreatectomy for PDAC was the same between young and elderly patients. Completion of planned AC was important, and lowered-dose AC using S1 for elderly patients might be safe and therapeutically useful.
BACKGROUND: The benefit of pancreatectomy for elderly patients with pancreatic ductal adenocarcinoma (PDAC) remains controversial. Moreover, adjuvant chemotherapy (AC) for elderly patients has not been fully evaluated. We investigated the long-term outcomes after pancreatectomy for PDAC in elderly patients with special reference to AC. METHODS: The medical records of 123 patients who underwent pancreatectomy for PDAC from 2007 to 2016 were retrospectively reviewed. The patients were divided into two groups: young (<75 years) and elderly patients (≥75 years). RESULTS: The study population comprised 91 young and 32 elderly patients. The postoperative clinical courses were not different between the two groups. AC was more frequently administered to young (85%) than elderly patients (66%; P = 0.04). The weekly dose of tegafur/gimeracil/oteracil potassium (S1) for AC was significantly lower in elderly (median 423 mg/m2) than young patients (median 491 mg/m2; P = 0.02). The prevalence of adverse events and the completion rate of AC were not significantly different between the two groups. There were no significant differences in recurrence-free survival (P = 0.73) or overall survival (P = 0.68) between the two groups in univariate analysis. Receipt of AC was not a significant independent factor for survival, and completion of planned AC was a significant independent factor for recurrence-free survival and overall survival in multivariate analysis. CONCLUSIONS: The benefit of pancreatectomy for PDAC was the same between young and elderly patients. Completion of planned AC was important, and lowered-dose AC using S1 for elderly patients might be safe and therapeutically useful.
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Reena Ravikumar; Caroline Sabin; Mohammad Abu Hilal; Simon Bramhall; Steven White; Stephen Wigmore; Charles J Imber; Giuseppe Fusai Journal: J Am Coll Surg Date: 2013-11-27 Impact factor: 6.113
Authors: Charles E Rutter; Henry S Park; Christopher D Corso; Nataniel H Lester-Coll; Brandon R Mancini; Debra N Yeboa; Kimberly L Johung Journal: Cancer Date: 2015-08-17 Impact factor: 6.860
Authors: Hari Nathan; Christopher L Wolfgang; Barish H Edil; Michael A Choti; Joseph M Herman; Richard D Schulick; John L Cameron; Timothy M Pawlik Journal: J Surg Oncol Date: 2009-02-01 Impact factor: 3.454
Authors: I Quintus Molenaar; Hjalmar C van Santvoort; Anne Claire Henry; Thijs J Schouten; Lois A Daamen; Marieke S Walma; Peter Noordzij; Geert A Cirkel; Maartje Los; Marc G Besselink; Olivier R Busch; Bert A Bonsing; Koop Bosscha; Ronald M van Dam; Sebastiaan Festen; Bas Groot Koerkamp; Erwin van der Harst; Ignace H J T de Hingh; Geert Kazemier; Mike S Liem; Vincent E de Meijer; Vincent B Nieuwenhuijs; Daphne Roos; Jennifer M J Schreinemakers; Martijn W J Stommel Journal: Ann Surg Oncol Date: 2022-06-02 Impact factor: 4.339